SIR-Spheresin 2nd-line Treatment of mCRC Investigator n Treatment ORR TTP/PFS Survival Lim30SIR-Spheres(+ 5FU/LV)70%33% 5.3 mo van Hazel 25SIR-Spheres+ irinotecan 48%6.0 mo12.2 mo 9.2 moL Limet al. BMC Cancer 2005;5:132. van Hazel et al. J...